Gilead Sciences, Inc [NASDAQ: GILD] price plunged by -1.61 percent to reach at -$1.73.
The one-year GILD stock forecast points to a potential upside of 7.15. The average equity rating for GILD stock is currently 1.87, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Gilead Sciences, Inc [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $113.64 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 1.87. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Gilead Sciences, Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 04, 2025. The new note on the price target was released on February 18, 2025, representing the official price target for Gilead Sciences, Inc stock. Previously, the target price had yet another raise to $108, while DZ Bank analysts kept a Buy rating on GILD stock. On January 10, 2025, analysts increased their price target for GILD shares from 87 to 113.
The Average True Range (ATR) for Gilead Sciences, Inc is set at 2.97, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 4.58. The Price to Book ratio for the last quarter was 6.80, with the Price to Cash per share for the same quarter was set at 9.28. Price to Free Cash Flow for GILD in the course of the last twelve months was 12.77 with Quick ratio for the last quarter at 1.45.
GILD Stock Performance Analysis:
Gilead Sciences, Inc [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.83. With this latest performance, GILD shares dropped by -10.13% in over the last four-week period, additionally plugging by 25.37% over the last 6 months – not to mention a rise of 51.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 39.52, with the RSI for the last a single of trading hit 32.06, and the three-weeks RSI is set at 44.97 for Gilead Sciences, Inc [GILD]. The present Moving Average for the last 50 days of trading for this stock 107.33, while it was recorded at 109.67 for the last single week of trading, and 89.36 for the last 200 days.
Insight into Gilead Sciences, Inc Fundamentals:
Gilead Sciences, Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.45 and a Current Ratio set at 1.60.
GILD Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc go to 25.00%.
Gilead Sciences, Inc [GILD] Institutonal Ownership Details
There are presently around $89.60%, or 89.70%% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 120.63 million shares, which is approximately 9.6738%. VANGUARD GROUP INC, holding 115.26 million shares of the stock with an approximate value of $$7.91 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $$5.23 billion in GILD stock with ownership which is approximately 6.1147%.
